Возможности лечения диабетической ретинопатии ингибиторами ангиогенеза (обзор литературы)
Ключевые слова:
диабетическая ретинопатия, интравитреальное введение, ингибиторы ангиогенеза, фактор роста эндотелия сосудовАннотация
Диабетическая ретинопатия является одной из социально значимых проблем в мировой офтальмологии ввиду значительного снижения зрительных функций и инвалидизации пациентов. В данной статье представлены недавние клинические исследования по лечению антиангиогенными препаратами непролиферативной и пролиферативной диабетической ретинопатии как в сочетании, так и без диабетического макулярного отека.
Библиографические ссылки
Нероев В.В., Киселёва Т.Н., Охоцимская Т.Д. и др. Влияние антиангиогенной терапии на глазной кровоток и микроциркуляцию при диабетическом макулярном отеке. Вестн. офтальмологии. 2018; 134(4):3-10.
Wells J.A., Glassman A.R., Ayala A.R. et al. Diabetic Retinopathy Clinical Research Net work. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351 1359.
Gangwani R.A., Lian J.X., McGhee S.M. et al. Diabetic retinopathy screening: global and local perspective. Hong Kong Med J. 2016; 22:486-495.
Бикбов М.М., Зайнуллин Р.М. и др. Результаты применения интравитреального имплантата дексаметазона озурдекс для лечения диабетического макулярного отека. Офтальмохирургия. 2020; 2:26-32.
Bikbov M., Gilmanshin T., Zainullin R., et al. Prevalence and associated factors of diabetic retinopathy in a russian population. The ural eye and medical study. Investigative Ophthalmology and Visual Science. – 2019. – Т. 60. – № 9. – С. 3959.
Бикбов М.М., Гильманшин Т.Р., Зайнуллин Р.М., Кудоярова К.И. К вопросу об эпидемиологии сахарного диабета и диабетической ретинопатии в Республике Башкортостан. // Acta Biomedica Scientifica. 2019. – Т. 4. – № 4. – С. 66-69.
Wei W., Amy C., Lo Y. Diabetic Retinopathy: Pathophysiology and Treatments. Int. J. Mol. Sci. 2018; 19(6):1816.
Staurenghi G., Feltgen N., Arnold J.J. for the VIVID-DME and VISTA-DME study investigators, et al. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. British Journal of Ophthalmology. 2018; 102:954-958.
Sophie C., Neil M.B. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr. Opin. Ophthalmol. 2017; 28(6):636-643.
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA). https://clinicaltrials.gov/ct2/show/ NCT02718326
Бикбов М.М., Зайнуллин Р.М., Гильманшин Т.Р., Халимов Т.А. Сравнительный анализ отдаленных результатов хирургического лечения диабетического макулярного отека и эпиретинальной мембраны. Офтальмология. 2019; 16(1):33-39.
Quan D.N., David M.B., Dennis M.M. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789-801.
Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographsan extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991; 98(5):786-806.
Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic Yonekawa et al 9 retinopathy. ETDRS report number 12. Ophthalmology. 1991; 98(5):823-833.
Будзинская М.В., Петрачков Д.В., Савочкина О.А., Аржуханов Д.Д. К вопросу о классификации диабетической ретинопатии. Вестн. офтальмологии. 2015; 135(5):272-277.
Yonekawa Y., Modi Y.S., Kim L.A. et al. American Society of Retina Specialists Clinical Practice Guidelines: Management of Nonproliferative and Proliferative Diabetic Retinopathy Without Diabetic Macular Edema. Journal of VitreoRetinal Diseases. 2020; 4(2):125-135.
Heier J.S., Korobelnik J.F., Brown D.M. et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016; 123(11):2376-2385.
Zhao Y., Singh R.P. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs in Context 2018; 7.
Wells J.A., Glassman A.R., Ayala A.R. Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-1359.
Bressler S.B., Liu D., Glassman A.R. et al. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017; 135(6):558-568.
Gross J.G., Glassman A.R., Jampol L.M. et al. Writing Committee for the Diabetic Retinopathy Clinical Research Network; Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015; 314(20):2137-2146.
Bressler S.B., Beaulieu W.T., Glassman A.R. et al. Diabetic Retinopathy Clinical Research Network. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology. 2017; 124(4):431–439.
Sivaprasad S., Prevost A.T., Vasconcelos J.C. et al. CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017; 389(10085):2193–2203.
Study of the efficacy and safety of intravitreal (IVT) aflibercept for the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR) – Full Text View. ClinicalTrials.gov [Internet] [Accessed February 23, 2018].
Lim J.I. Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: Year 2 Results from the PANORAMA Study. Investigative Ophthalmology & Visual Science. 2020; 61:1381.
Wykoff C.C. Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study. Data presented at: Angiogenesis, Exudation and Degeneration Annual Meeting; Miami, FL. 2020.
Anti-VEGF Treatment for Prevention of PDR/DME. https://clinicaltrials.gov/ct2/show/study/NCT02634333
